Medication info
Hyduang Duo Extended Release Tablet 25/1000 mg (Empagliflozin, Metformin)

Hyduang Duo Extended Release Tablet 25/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Huons Co., Ltd.
Appearance
Light yellow, oval, bi-convex extended release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501553 · Approved 2025.06.23 · Insurance code 670609550

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily in the evening with a meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one tablet of this drug 10/1000 mg extended-release or 25/1000 mg extended-release once daily. Patients taking this drug 5/1000 mg extended-release or 12.5/1000 mg extended-release should take 2 tablets together once daily. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. For patients whose blood glucose cannot be adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment based on renal function is necessary, renal function should be assessed before treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this drug may be used with the following adjustment to the metformin hydrochloride dose. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this drug should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into account.

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes

  • Abnormal blood sugar control in adults with type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used as an adjunct to diet and exercise for improvements in blood sugar control in adult patients with type 2 diabetes. It is particularly effective for patients whose blood sugar is not adequately controlled. Additionally, caution is advised in patients with established cardiovascular disease; therefore, guidance from a healthcare professional should be strictly followed. This medication should be used considering blood sugar management and cardiovascular safety.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily in the evening with a meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one tablet of this drug 10/1000 mg extended-release or 25/1000 mg extended-release once daily. Patients taking this drug 5/1000 mg extended-release or 12.5/1000 mg extended-release should take 2 tablets together once daily. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. For patients whose blood glucose cannot be adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment based on renal function is necessary, renal function should be assessed before treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this drug may be used with the following adjustment to the metformin hydrochloride dose. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this drug should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into account.

Precautions

This medication is used in diabetes treatment and contains two ingredients that assist in blood sugar control. However, it should not be used in patients with impaired kidney function or certain serious conditions. Particularly, if kidney function is moderately impaired or worse, taking this medication may pose health risks, so patients should consult a doctor. Furthermore, this medication should be discontinued in the presence of severe infections, dehydration, heart failure, or acute myocardial infarction. Hypoglycemic symptoms may occur during treatment, so caution is needed when used with insulin or other hypoglycemic agents. Kidney and liver functions should be regularly monitored for abnormalities during treatment. Also, gastrointestinal disorders, urinary tract infections, genital infections, and increased urination may occur, so patients should promptly inform their physician if such symptoms arise. This medication can cause a rare but serious side effect called lactic acidosis, so immediate medical attention is required if symptoms such as vomiting, abdominal pain, weakness, or difficulty breathing appear. It is advisable for pregnant women, those who may become pregnant, and nursing women not to take this medication. Elderly patients or those at risk of decreased fluid levels should be more cautious when taking this medication and should be closely monitored for dehydration and cardiovascular irregularities. This medication must be taken strictly according to a doctor's prescription and guidance, and potential interactions with other medications should also be considered. When swallowing the tablets, they should not be crushed or chewed; they should be swallowed whole, and the tablet coating passing in the stool is normal. In case of overdose, serious side effects may occur, so appropriate treatment should be sought immediately.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
Show 143 more
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • dysgeusia
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • vaginismus
  • vulvitis
  • glans inflammation
  • perineal necrosis
  • nausea
  • malaise
  • gastric ulcer
  • colitis
  • ischemic colitis
  • bowel hemorrhage
  • chronic gastritis
  • headache
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic carcinoma
  • constipation
  • gastritis
  • dry mouth
  • gastrointestinal disturbance
  • oral discomfort
  • salivary gland pain
  • upper respiratory infection
  • bronchitis
  • chronic sinusitis
  • gastroenteritis
  • Helicobacter infection
  • periodontitis
  • chronic tonsillitis
  • conjunctivitis
  • influenza
  • laryngitis
  • meningitis
  • chronic otitis media
  • paronychia
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tinea corporis
  • dental abscess
  • adnexal abscess
  • vestibular neuritis
  • nasopharyngitis
  • position-related dizziness
  • sensory loss
  • paresthesia
  • amnesia
  • carotid stenosis
  • diabetic neuropathy
  • facial paralysis
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • drowsiness
  • CNS origin vertigo
  • fatigue
  • peripheral edema
  • facial swelling
  • peripheral swelling
  • fever
  • facial swelling
  • chills
  • strange sensation
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • chest pain
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • epistaxis
  • asthma
  • exertional dyspnoea
  • productive cough
  • allergic rhinitis
  • residual phlegm
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • falls
  • hand fracture
  • iliotibial band syndrome
  • open eye injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular disease
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorder
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • position-related vertigo
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Light yellow, oval, bi-convex extended release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.